ClinicalTrials.gg
CompletedNCT00835978Updated May 30, 2017Results posted

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

A Phase 2 interventional study of axitinib and axitinib in Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 65 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
7th of 41
213 · median 40
Started
2009
the only one that year
Phase 2
29 of 41
9 open now
Registered
3rd of 41
by date
Lead sponsor
6 of 41
Pfizer

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 29 in phase 2, and was the 3rd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • axitinib or AG-013736 dose titration (increase) renal cell carcinoma
  • kidney cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • renal cell carcinoma (kidney cancer) with clear cell component
  • no prior systemic therapy (including no prior adjuvant or )
  • (ECOG) Performance Status 0-1
  • Blood Pressure \< or = 140/90mmHg

Exclusion criteria

Exclusion Criteria:

  • brain/
  • using more than 2 blood pressure medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
213 participants (actual)

Study arms

  • Other
    A

    Randomized arm

    Drug: axitinib

  • Other
    B

    Randomized arm

    Drug: axitinib

  • Other
    C

    Non-randomized arm

    Drug: axitinib

Interventions

  • axitinib 5mg BID (open-label) + axitinib dose titration (blinded)

  • axitinib 5mg BID (open-label) + placebo dose titration (blinded)

  • axitinib 5mg BID (open-label)

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) - Percentage of Participants With Objective Response

    ORR was defined as the proportion of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    The time from first dose administration to first documentation of objective tumor progression or to death due to any cause. PFS in each arm was assessed using the Kaplan-Meier method and estimates of the PFS curves from the Kaplan-Meier method were presented.

    Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.

  2. Duration of Response (DR)

    DR was defined as the time from the first documentation of objective tumor response (complete response - CR or Partial response - PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. The median values were estimated based on Kaplan-Meier method. 95% confidence interval was based on the Brookmeyer and Crowley method.

    Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks

  3. Overall Survival (OS)

    OS was defined as the time from date of the first dose of the study medication to date of death due to any cause. For participants who did not die, their survival times were to be censored at the last date they were known to be alive.

    Time frame: Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.

  4. Maximum Observed Plasma Concentration (Cmax) of Axitinib

    Cmax for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

    Time frame: Cycle 2 Day 15 (C2D15): pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib,

    Tmax for steady-state axitinib was evaluated on Cycle 2 Day 15.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib

    Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  7. Area Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib

    Area under the plasma concentration time-curve from zero 24 hours\[AUC(0-24). AUC(0-24) for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  8. Plasma Decay Half-Life (t1/2) for Axitinib

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for steady-state axitinib was evaluated on Cycle 2 Day 15.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  9. Apparent Oral Clearance (CL/F) of Axitinib

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for steady-state axitinib was evaluated on Cycle 2 Day 15.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  10. Apparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for steady-state axitinb was evaluated on Cycle 2 Day 15.

    Time frame: C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose

  11. Change From Baseline in Systolic Blood Pressure

    Value at respective visit minus value at baseline

    Time frame: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.

  12. Change From Baseline in Diastolic Blood Pressure

    Value at respective visit minus value at baseline.

    Time frame: At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.

  13. Comparison of Circulating Endothelial Cells (CECs) in Blood: Cluster of Differentiation (CD)146+/CD105+ at Baseline

    CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ mean fluorescence intensity (MFI) platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-Vascular endothelial growth factor receptor (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

    Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)

  14. Comparison of the Ratio of CECs in Blood: CD146+/CD105+ at Each Time Point to Baseline

    CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ MFI platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-VEGFR (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

    Time frame: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)

  15. Circulating Endothelial Cells (CECs) in Blood: CD31+/CD146+

    CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

    Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)

  16. Comparison of Ratio of CECs in Blood: CD31+/CD146+ at Each Time Point to Baseline

    CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

    Time frame: At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)

  17. ORR in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms

    ORR, defined as proportion of participants with CR or PR according to RECIST, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms.

    Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)

  18. PFS in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms

    PFS, defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. Estimates of the PFS curves from the Kaplan-Meier method were presented.

    Time frame: At baseline - Beginning of the lead-in period (Cycle 1 Day 1)

07

Results

Posted May 26, 2014

Participant flow

This study was conducted at 49 centers in Czech Republic, Germany, Japan, Russian Federation, Spain, and the United States (US).

Participant flow — Overall Study
MilestoneActive Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to Randomization
Started56569110
Treated56569110
Completed0000
Not completed56569110
Withdrew: Death3340494
Withdrew: Lost to follow-up3421
Withdrew: Other5180
Withdrew: Objective progression or relapse2010
Withdrew: Adverse event1010
Withdrew: Withdrawal by subject0305
Withdrew: Study terminated by sponsor128300

Outcome measures

PrimaryObjective Response Rate (ORR) - Percentage of Participants With Objective Response

ORR was defined as the proportion of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR was defined as complete disappearance of all target lesions and non-target disease. No new lesions. PR was defined as \>=30% decrease on study under baseline of the sum of longest diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response
Percentage of ParticipantsActive Titration ArmPlacebo Titration ArmNon-randomized ArmAll Participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response53.6 (39.7 to 67.0)33.9 (21.8 to 47.8)59.3 (48.5 to 69.5)48.4 (41.5 to 55.3)
Statistical analysis
  • Active Titration Arm vs Placebo Titration Arm · Cochran-Mantel-Haenszel · p = 0.0189 (A priori defined threshold for statistical significance was: alpha=0.10 (one-sided)) · Risk ratio (rr): 1.578 · 95% CI 1.017 to 2.448
SecondaryProgression-Free Survival (PFS)

The time from first dose administration to first documentation of objective tumor progression or to death due to any cause. PFS in each arm was assessed using the Kaplan-Meier method and estimates of the PFS curves from the Kaplan-Meier method were presented.

Time frame:
Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsActive Titration ArmPlacebo Titration ArmNon-randomized ArmAll Participants
Progression-Free Survival (PFS)14.5 (9.2 to 24.5)15.7 (8.3 to 19.4)16.6 (11.2 to 22.5)14.6 (11.5 to 17.5)
Statistical analysis
  • Active Titration Arm vs Placebo Titration Arm · Log Rank · p = 0.2444 · Hazard ratio (hr): 0.849 · 95% CI 0.535 to 1.348
SecondaryDuration of Response (DR)

DR was defined as the time from the first documentation of objective tumor response (complete response - CR or Partial response - PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. The median values were estimated based on Kaplan-Meier method. 95% confidence interval was based on the Brookmeyer and Crowley method.

Time frame:
Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks
Reported as:
Median · Months
Duration of Response (DR)
MonthsActive Titration ArmPlacebo Titration ArmNon-randomized Arm
Duration of Response (DR)NA (10.8 to NA)21.2 (11.1 to 25.8)23.3 (15.7 to 28.6)
SecondaryOverall Survival (OS)

OS was defined as the time from date of the first dose of the study medication to date of death due to any cause. For participants who did not die, their survival times were to be censored at the last date they were known to be alive.

Time frame:
Baseline up to disease progression, death, or withdrawal; performed at baseline and repeated every 8 weeks for 24 weeks, then every 12 weeks.
Reported as:
Median · Months
Overall Survival (OS)
MonthsActive Titration Arm (FA Population)Placebo Titration Arm (FA Population)Non-randomized Arm (SA Population)
Overall Survival (OS)42.7 (24.7 to NA)30.4 (23.7 to 45.0)41.6 (33.0 to NA)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Axitinib

Cmax for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

Time frame:
Cycle 2 Day 15 (C2D15): pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Axitinib
ng/mLActive Titration ArmPlacebo Titration Arm
Maximum Observed Plasma Concentration (Cmax) of Axitinib31.74 (21.63 to 46.58)23.05 (16.36 to 32.49)
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib,

Tmax for steady-state axitinib was evaluated on Cycle 2 Day 15.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib,
hrsActive Titration ArmPlacebo Titration Arm
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib,2.04 (1.00 to 6.00)2.00 (0.00 to 6.00)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib

Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Geometric mean · ng.hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib
ng.hr/mLActive Titration ArmPlacebo Titration Arm
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Axitinib105.33 (70.16 to 158.14)78.44 (54.53 to 112.82)
SecondaryArea Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib

Area under the plasma concentration time-curve from zero 24 hours\[AUC(0-24). AUC(0-24) for steady-state axitinib was evaluated on Cycle 2 Day 15. Results were normalized to axitinib 7 mg dose for active titration arm and axitinib 5 mg dose for placebo titration arm.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Geometric mean · ng.hr/mL
Area Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib
ng.hr/mLActive Titration ArmPlacebo Titration Arm
Area Under the Curve From Time Zero to 24 Hours[AUC(0-24)] for Axitinib258.68 (150.47 to 444.72)161.38 (102.09 to 255.12)
SecondaryPlasma Decay Half-Life (t1/2) for Axitinib

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for steady-state axitinib was evaluated on Cycle 2 Day 15.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2) for Axitinib
hrActive Titration ArmPlacebo Titration Arm
Plasma Decay Half-Life (t1/2) for Axitinib2.48 ± 1.9022.81 ± 1.685
SecondaryApparent Oral Clearance (CL/F) of Axitinib

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for steady-state axitinib was evaluated on Cycle 2 Day 15.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F) of Axitinib
L/hrActive Titration ArmPlacebo Titration Arm
Apparent Oral Clearance (CL/F) of Axitinib54.15 (31.49 to 93.12)61.93 (39.17 to 97.91)
SecondaryApparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for steady-state axitinb was evaluated on Cycle 2 Day 15.

Time frame:
C2D15: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib
LActive Titration ArmPlacebo Titration Arm
Apparent Volume of Distribution During the Elimination Phase (Vz/F) for Axitinib158.18 (98.38 to 254.34)216.62 (145.00 to 323.60)
SecondaryChange From Baseline in Systolic Blood Pressure

Value at respective visit minus value at baseline

Time frame:
At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure
mmHgActive Titration ArmPlacebo Titration ArmNon-randomized Arm
Cycle 1 Day 1 (n=52,51,73)-4.3 ± 11.1-2.9 ± 9.2-1.8 ± 14.2
Cycle 1 Day 15 (n=56,56,91)3.8 ± 12.24.1 ± 12.511.5 ± 18.0
Cycle 2 Day 1 (n=56,56,91)1.9 ± 12.40.9 ± 13.69.9 ± 18.7
Cycle 2 Day 15 (n=55,55,86)3.6 ± 13.82.7 ± 16.65.9 ± 20.3
Cycle 3 Day 1 (n=48,49,84)3.5 ± 15.18.4 ± 15.45.2 ± 20.2
Cycle 4 Day 1 (n=45,48,79)4.3 ± 12.73.5 ± 13.05.5 ± 18.2
End of treatment (n=35,44,51)2.4 ± 17.01.7 ± 14.0-2.8 ± 19.0
Follow-up (n=16,25,36)-3.6 ± 16.9-0.4 ± 16.3-0.6 ± 16.7
SecondaryChange From Baseline in Diastolic Blood Pressure

Value at respective visit minus value at baseline.

Time frame:
At screening (D-14 to D-1); lead-in period: Cycle 1 - Day 1 and Day 15; Cycle 2 - Day 1 and Day 15; Cycle 3 & subsequent cycles Day 1; end of study and follow-up 28 days after last dose.
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure
mmHgActive Titration ArmPlacebo Titration ArmNon-randomized Arm
Cycle 1 Day 1 (n=52,51,73)-1.6 ± 8.2-2.6 ± 7.40.5 ± 8.4
Cycle 1 Day 15 (n=56,56,91)4.8 ± 8.53.0 ± 7.711.5 ± 10.0
Cycle 2 Day 1 (n=56,56,91)4.2 ± 9.03.5 ± 8.010.5 ± 10.5
Cycle 2 Day 15 (n=55,55,86)5.5 ± 10.54.4 ± 10.79.7 ± 11.3
Cycle 3 Day 1 (n=48,49,84)6.6 ± 8.35.9 ± 9.39.1 ± 13.6
Cycle 4 Day 1 (n=45,48,79)7.4 ± 8.24.6 ± 8.58.7 ± 11.8
End of treatment (n=35,44,51)0.6 ± 10.83.5 ± 6.33.0 ± 10.5
Follow-up (n=16,25,36)-4.5 ± 10.1-1.3 ± 8.51.8 ± 9.0
SecondaryComparison of Circulating Endothelial Cells (CECs) in Blood: Cluster of Differentiation (CD)146+/CD105+ at Baseline

CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ mean fluorescence intensity (MFI) platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-Vascular endothelial growth factor receptor (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

Time frame:
At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Reported as:
Mean · Fluorescent Intensity Unit (FIU)
Comparison of Circulating Endothelial Cells (CECs) in Blood: Cluster of Differentiation (CD)146+/CD105+ at Baseline
Fluorescent Intensity Unit (FIU)Active Titration ArmPlacebo Titration ArmNon-randomized Arm
Baseline CECs Count (n=17,22,20)23584 ± 18213.128544 ± 27694.429663 ± 30651.0
Baseline MFI PDGFR-BETA (n=17,22,20)346815 ± 179563455238 ± 238157327567 ± 167728
Baseline MFI pPDGFR-BETA (n=17,22,20)401226 ± 195445395509 ± 136933397672 ± 193172
Baseline MFI pVEGFR (n=16,22,20)456086 ± 290174436197 ± 128225398754 ± 188137
Baseline MFI VEGFR (n=16,22,20)367799 ± 181320473290 ± 228619359092 ± 167706
SecondaryComparison of the Ratio of CECs in Blood: CD146+/CD105+ at Each Time Point to Baseline

CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD146+/CD105+ CECs, CD146+/CD105+ MFI platelet derived growth factor receptor (PDGFR)-beta, CD146+/CD105+ MFI phospho-PDGFR (pPDGFR)-beta, CD146+/CD105+ phospho-VEGFR (pVEGFR), CD146+/CD105+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

Time frame:
At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
Reported as:
Mean · Ratio
Comparison of the Ratio of CECs in Blood: CD146+/CD105+ at Each Time Point to Baseline
RatioActive Titration ArmPlacebo Titration ArmNon-randomized Arm
C1D15:C1D1 CECs Count (n=11,18,14)2.3 ± 2.523.7 ± 6.922.2 ± 3.10
C2D15:C1D1 CECs Count (n=13,16,11)1.3 ± 1.434.4 ± 9.271.3 ± 1.22
EOT:C1D1 CECs Count (n=7,9,4)2.8 ± 4.818.9 ± 21.701.2 ± 1.50
C1D15:C1D1 MFI PDGFRBETA (n=11,17,13)1.3 ± 1.031.5 ± 1.141.1 ± 0.73
C2D15:C1D1 MFI PDGFRBETA (n=13,16,11)1.4 ± 1.241.1 ± 1.142.2 ± 1.62
EOT:C1D1 MFI PDGFRBETA (n=7,9,4)1.5 ± 1.750.6 ± 0.521.2 ± 1.78
C1D15:C1D1 MFI pPDGFR-BETA (n=11,17,13)1.1 ± 0.631.2 ± 0.771.0 ± 1.12
C2D15:C1D1 MFI pPDGFR-BETA (n=13,16,11)1.0 ± 0.690.8 ± 0.451.2 ± 0.79
EOT:C1D1 MFI pPDGFRBETA (n=7,9,4)0.8 ± 0.710.8 ± 0.931.9 ± 1.57
C1D15:C1D1 MFI pVEGFR (n=10,18,14)1.0 ± 0.461.2 ± 0.881.2 ± 1.00
C2D15:C1D1 MFI pVEGFR (n=12,16,11)1.0 ± 0.740.9 ± 0.821.2 ± 0.80
EOT:C1D1 MFI pVEGFR (n=7,9,4)0.8 ± 0.531.3 ± 0.963.0 ± 1.16
C1D15:C1D1 MFI VEGFR (n=10,18,14)1.4 ± 1.251.3 ± 0.941.0 ± 0.64
C2D15:C1D1 MFI VEGFR (n=12,16,11)1.5 ± 1.481.3 ± 0.992.1 ± 1.72
EOT:C1D1 MFI VEGFR (n=7,9,4)1.1 ± 1.030.7 ± 0.481.9 ± 1.63
SecondaryCirculating Endothelial Cells (CECs) in Blood: CD31+/CD146+

CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

Time frame:
At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Reported as:
Mean · Fluorescent Intensity Unit (FIU)
Circulating Endothelial Cells (CECs) in Blood: CD31+/CD146+
Fluorescent Intensity Unit (FIU)Active Titration ArmPlacebo Titration ArmNon-randomized Arm
Baseline CECs Count (n=17,22,20)74668 ± 50558.976258 ± 46779.577437 ± 63419.4
Baseline MFI PDGFR-BETA (n=17,21,20)333760 ± 164604380886 ± 147261442642 ± 267436
Baseline MFI pPDGFR-BETA (n=17,21,20)380139 ± 205600355441 ± 147046383202 ± 211174
Baseline MFI pVEGFR (n=17,22,20)385617 ± 203956352644 ± 128803380184 ± 173578
Baseline MFI VEGFR (n=17,22,20)330333 ± 151710401909 ± 165235359097 ± 146943
SecondaryComparison of Ratio of CECs in Blood: CD31+/CD146+ at Each Time Point to Baseline

CECs are noninvasive marker of vascular damage, remodeling, and dysfunction. Samples were collected and following proteins were analyzed: CD31+/CD146+ CECs, CD31+/CD146+ MFI PDGFR-beta, CD31+/CD146+ MFI pPDGFR-beta, CD31+/CD146+ pVEGFR, CD31+/CD146+ MFI VEGFR. The ratio of plasma levels of the biomarkers at the selected time point vs baseline is reported.

Time frame:
At end of the lead-in period (Cycle 1 Day 15), Cycle 2 Day 15 and End of therapy (EOT)
Reported as:
Mean · Ratio
Comparison of Ratio of CECs in Blood: CD31+/CD146+ at Each Time Point to Baseline
RatioActive Titration ArmPlacebo Titration ArmNon-randomized Arm
C1D15:C1D1 CECs Count (n=11,18,14)2.7 ± 3.171.6 ± 2.321.5 ± 2.31
C2D15:C1D1 CECs Count (n=13,16,11)1.4 ± 1.382.2 ± 3.912.5 ± 3.98
EOT:C1D1 CECs COUNT (n=7,9,4)1.5 ± 1.951.4 ± 2.660.6 ± 0.71
C1D15:C1D1 MFI PDGFRBETA (n=11,15,13)1.2 ± 0.741.3 ± 0.890.8 ± 0.51
C2D15:C1D1 MFI PDGFRBETA (n=13,14,11)1.4 ± 1.361.1 ± 1.032.2 ± 2.64
EOT:C1D1 MFI PDGFRBETA (n=6,8,4)1.2 ± 1.230.6 ± 0.511.7 ± 1.49
C1D15:C1D1 MFI pPDGFR-BETA (n=11,15,13)1.2 ± 1.071.4 ± 0.811.0 ± 0.87
C2D15:C1D1 MFI pPDGFR-BETA (n=13,14,11)1.2 ± 0.890.8 ± 0.381.1 ± 0.71
EOT:C1D1 MFI pPDGFRBETA (n=6,8,4)0.7 ± 0.630.8 ± 0.913.0 ± 0.47
C1D15:C1D1 MFI pVEGFR (n=11,18,14)1.1 ± 0.751.4 ± 0.741.2 ± 0.90
C2D15:C1D1 MFI pVEGFR (n=13,16,10)1.2 ± 1.000.9 ± 0.681.3 ± 0.70
EOT:C1D1 MFI pVEGFR (n=7,9,4)0.7 ± 0.591.1 ± 1.243.1 ± 0.95
C1D15:C1D1 MFI VEGFR (n=11,18,14)1.3 ± 0.931.3 ± 0.901.0 ± 0.57
C2D15:C1D1 MFI VEGFR n=13,16,10)1.5 ± 1.441.2 ± 0.962.1 ± 1.80
EOT:C1D1 MFI VEGFR (n=7,9,4)1.2 ± 1.271.1 ± 0.901.5 ± 1.42
SecondaryORR in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms

ORR, defined as proportion of participants with CR or PR according to RECIST, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms.

Time frame:
At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Reported as:
Number · Percentage of participants
ORR in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms
Percentage of participantsActive Titration ArmPlacebo Titration ArmNon-randomized Arm
VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14)85.7 (42.1 to 99.6)22.2 (2.8 to 60.0)42.9 (17.7 to 71.1)
VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41)54.5 (32.2 to 75.6)35.0 (15.4 to 59.2)65.9 (49.4 to 79.9)
VEGFA/rs699947 Genotype: C/C (n = 14, 14, 24)50.0 (23.0 to 77.0)35.7 (12.8 to 64.9)66.7 (44.7 to 84.4)
VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43)59.1 (36.4 to 79.3)39.1 (19.7 to 61.5)67.4 (51.5 to 80.9)
VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29)57.9 (33.5 to 79.7)18.8 (4.0 to 45.6)58.6 (38.9 to 76.5)
VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 7)50.0 (1.3 to 98.7)50.0 (6.8 to 93.2)42.9 (9.9 to 81.6)
VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28)81.3 (54.4 to 96.0)53.3 (26.6 to 78.7)60.7 (40.6 to 78.5)
VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35)45.5 (24.4 to 67.8)18.2 (5.2 to 40.3)57.1 (39.4 to 73.7)
VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16)40.0 (5.3 to 85.3)33.3 (4.3 to 77.7)75.0 (47.6 to 92.7)
VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 79)58.3 (40.8 to 74.5)30.8 (17.0 to 47.6)64.3 (51.9 to 75.4)
VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9)50.0 (11.8 to 88.2)50.0 (6.8 to 93.2)44.4 (13.7 to 78.8)
VEGFR3/rs307826 Genotype: G/G (n = 1, 0, 0)100.0 (2.5 to 100.0)0 (0.0 to 0.0)0 (0.0 to 0.0)
VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 79)55.6 (38.1 to 72.1)28.9 (15.4 to 45.9)65.2 (52.8 to 76.3)
VEGFR3/rs307821 Genotype: G/T (n = 6, 5, 10)66.7 (22.3 to 95.7)60.0 (14.7 to 94.7)40.0 (12.2 to 73.8)
VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0)100.0 (2.5 to 100.0)0 (0.0 to 0.0)0 (0.0 to 0.0)
SecondaryPFS in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms

PFS, defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause, in subgroups that were defined by VEGFA or VEGFR3 polymorphisms. Estimates of the PFS curves from the Kaplan-Meier method were presented.

Time frame:
At baseline - Beginning of the lead-in period (Cycle 1 Day 1)
Reported as:
Median · Months
PFS in Subgroups That Were Defined by Vascular Endothelial Growth Factor A (VEGFA) or Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Polymorphisms
MonthsActive Titration ArmPlacebo Titration ArmNon-randomized Arm
VEGFA/rs699947 Genotype: A/A (n = 7, 9, 14)NA (1.74 to NA)11.50 (3.58 to NA)7.33 (5.06 to 13.83)
VEGFA/rs699947 Genotype: A/C (n = 22, 20, 41)11.07 (3.02 to 17.44)9.67 (1.91 to 16.59)16.59 (10.97 to NA)
VEGFA/rs699947 Genotype: C/C (n = 14, 14, 41)18.74 (1.84 to NA)24.64 (4.01 to NA)25.13 (8.28 to 30.45)
VEGFA/rs1570360 Genotype: G/G (n = 22, 23, 43)14.62 (7.39 to NA)19.42 (5.81 to 27.63)25.13 (11.47 to 30.45)
VEGFA/rs1570360 Genotype: G/A (n = 19, 16, 29)12.78 (1.84 to NA)8.34 (1.91 to 16.59)13.90 (8.28 to 22.54)
VEGFA/rs1570360 Genotype: A/A (n = 2, 4, 29)NA (1.74 to NA)10.04 (3.58 to NA)8.57 (1.74 to NA)
VEGFR3/rs448012 Genotype: G/G (n = 16, 15, 28)17.44 (12.78 to NA)19.42 (5.35 to NA)22.54 (8.08 to NA)
VEGFR3/rs448012 Genotype: G/C (n = 22, 22, 35)9.18 (1.84 to NA)8.31 (3.58 to 16.52)13.83 (5.62 to 16.59)
VEGFR3/rs448012 Genotype: C/C (n = 5, 6, 16)11.07 (1.84 to NA)15.67 (1.91 to 27.63)NA (8.57 to NA)
VEGFR3/rs307826 Genotype: A/A (n = 36, 39, 70)13.73 (8.28 to 24.47)15.67 (8.21 to 22.17)16.56 (10.28 to 25.13)
VEGFR3/rs307826 Genotype: A/G (n = 6, 4, 9)16.52 (1.18 to NA)7.93 (1.84 to 11.86)16.26 (2.66 to 30.45)
VEGFR3/rs307826 Genotype: G/G (n = 0, 0, 0)NA (NA to NA)NA (NA to NA)NA (NA to NA)
VEGFR3/rs307821 Genotype: G/G (n = 36, 38, 69)12.78 (7.39 to 24.47)15.67 (8.21 to 23.95)16.59 (10.28 to 28.52)
VEGFR3/rs307821 Genotype: G/T (n = 36, 38, 10)24.80 (1.18 to NA)8.34 (1.84 to 11.86)13.86 (2.66 to 30.45)
VEGFR3/rs307821 Genotype: T/T (n = 1, 0, 0)NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over AEs were reported until follow up visit. Non-SAEs: up to 28 days post last dose or upon starting new anticancer treatment, whichever was first. SAEs: up to 28 days post last dose, irrespective of new anticancer treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Titration Arm—25/56 (44.6%)55/56 (98.2%)
Placebo Titration Arm—14/56 (25%)51/56 (91.1%)
Non-randomized Arm—39/91 (42.9%)91/91 (100%)
Discontinued Prior to Randomization—2/10 (20%)9/10 (90%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventActive Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to Randomization
DehydrationMetabolism and nutrition disorders5/560/563/911/10
HypercalcaemiaMetabolism and nutrition disorders0/560/560/911/10
Renal failureRenal and urinary disorders0/560/560/911/10
Hypertensive crisisVascular disorders0/560/560/911/10
Myocardial infarctionCardiac disorders4/560/562/910/10
Disease progressionGeneral disorders1/561/566/910/10
VomitingGastrointestinal disorders3/561/561/910/10
PneumoniaInfections and infestations3/562/561/910/10
DiarrhoeaGastrointestinal disorders2/561/561/910/10
NauseaGastrointestinal disorders2/560/560/910/10
Most frequent other events
Showing 10 of 108
Most frequent other events
EventActive Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to Randomization
HypertensionVascular disorders35/5624/5676/915/10
DiarrhoeaGastrointestinal disorders34/5635/5658/911/10
FatigueGeneral disorders27/5626/5649/914/10
DysphoniaRespiratory, thoracic and mediastinal disorders18/5620/5644/913/10
HypothyroidismEndocrine disorders18/5613/5641/912/10
ProteinuriaRenal and urinary disorders12/5612/5640/912/10
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders18/5610/5640/910/10
NauseaGastrointestinal disorders24/5619/5633/912/10
Decreased appetiteMetabolism and nutrition disorders21/5616/5637/913/10
VomitingGastrointestinal disorders18/5612/5625/912/10

Baseline characteristics

The safety analysis (SA) population consists of all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Active Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to RandomizationTotal
Mean59.7 ± 10.259.6 ± 10.562.9 ± 8.962.9 ± 7.561.2 ± 9.7
Age, Customized
Age, Customized(Participants)Active Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to RandomizationTotal
< 65 Years3838546136
>= 65 Years181837477
Sex: Female, Male
Sex: Female, Male(Participants)Active Titration ArmPlacebo Titration ArmNon-randomized ArmDiscontinued Prior to RandomizationTotal
Female191136470
Male3745556143
08

Study locations

65 sites
  • East Bay Medical Oncology/Hematology Medical Associates Inc.
    Antioch, California 94531, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Bay Area Cancer Research Group, LLC
    Pleasant Hill, California 94523, United States
  • Diablo Valley Oncology and Hematology Medical Group Inc
    Pleasant Hill, California 94523, United States
  • East Bay Medical Oncology/Hematology Medical Associates Inc
    Pleasant Hill, California 94523, United States
  • East Bay Medical Oncology/Hematology Medical Associates Inc
    San Leandro, California 94578, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Investigational Drug Services, IUHSCC
    Indianapolis, Indiana 46202, United States
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110-1094, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • The University Hospital
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University, James Cancer Hospital
    Columbus, Ohio 43210, United States
  • JamesCare in Kenny
    Columbus, Ohio 43221, United States
  • West Chester Hospital Medical Building
    West Chester, Ohio 45069, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Texas Oncology, Sammons Cancer Center
    Dallas, Texas 75246, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4004, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Masarykuv onkologicky ustav
    Brno, CZE 656 53, Czechia
  • Fakultni nemocnice Olomouc Onkologicka klinika
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice Na Bulovce
    Praha 8, 180 81, Czechia
  • Krajska zdravotni, a.s. - Masarykova nemocnice V Usti nad Labem, o.z.
    Usti nad Labem, 401 13, Czechia
  • Universitaetsklinikum Duesseldorf
    Duesseldorf, 40225, Germany
  • Klinikum der J. W. Goethe-Universitaet, Medizinische Klinik II
    Frankfurt, 60590, Germany
  • Medizinische Hochschule Hannover, Abt. Haematologie, Haemostaseologie & Onkologie
    Hannover, 30625, Germany
  • Eberhardt-Karls-Universitaet Tuebingen, Klinik fuer Urologie
    Tuebingen, 72076, Germany
  • Klinikum Weiden Klinik fuer Urologie, Andrologie und Kinderurologie
    Weiden, 92637, Germany
  • Nagoya University Hospital
    Nagoya, Aichi 466-8560, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido 060-8543, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8638, Japan
  • Kobe University Hospital
    Kobe, Hyogo 650-0017, Japan
  • Kinki University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Hamamatsu University School of Medicine, University Hospital
    Hamamatsu-City, Shizuoka 431-3192, Japan
  • National Cancer Center
    Chuo-ku, Tokyo 104-0045, Japan
  • Japanese Foundation For Cancer Research Cancer Institute Hospital
    Koto-ku, Tokyo 135-8550, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Akita University Hospital
    Akita, 010-8543, Japan
  • Chiba Cancer Center
    Chiba, 260-8717, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
  • Yamagata University Hospital
    Yamagata, 990-9585, Japan
  • Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia
    Obninsk, Kaluga Region 249036, Russian Federation
  • State Healthcare Institution "Leningrad Regional Oncology Dispensary"
    Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast 188663, Russian Federation
  • FSBSI "N.N. Blokhin Russian Cancer Research Center"
    Moscow, 115478, Russian Federation
  • FSBI"Russian Scientific Center of Roengenoradiology" of the MH of RF
    Moscow, 117997, Russian Federation
  • Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary'
    Saint-Petersburg, 197022, Russian Federation
  • Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary'
    Saint-Petersburg, 198255, Russian Federation
  • GBUZ "Samara Regional Clinical Oncology Dispensary"
    Samara, 443031, Russian Federation
  • Hospital de La Princesa
    Madrid, 28006, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6. PubMed 30616534 ↗
  • de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21. PubMed 28410911 ↗
  • Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26. PubMed 27238653 ↗
  • Rini BI, Melichar B, Ueda T, Grunwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18. Erratum In: Lancet Oncol. 2014 Jun;15(7):e253. PubMed 24140184 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Oct 2012 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 4, 2009
Start
Aug 2009
Primary completionActual
Oct 2012
CompletionActual
Feb 2016
Results first posted
May 26, 2014
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00835978
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 4, 2009
Start date
Aug 2009
Primary completion
Oct 2012
Completion
Feb 2016
Results posted
May 26, 2014
Last update
May 30, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion